Renagade Therapeutics Launches with $300 Million to Expand Reach of RNA Therapies

Rare Daily Staff

Renagade Therapeutics, which is seeking to expand the utility of RNA therapeutics by delivering them anywhere in the body that they are needed, completed a $300 million series A financing.

MPM BioImpact and F2 Ventures led the financing round.

Renagade said it has built a comprehensive and complementary platform that combines its proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools, in an all-RNA system.

The company is addressing limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body, substantially expanding the potential addressable disease market. Renagade has an established joint venture with Orna Therapeutics to combine Renagade’s delivery platform with Orna’s circular RNA technology. Subsequently, Orna has entered into a collaboration with Merck, which includes technologies developed under the Orna/Renagade joint venture.

Founded by MPM BioImpact, ReNAgade is led by Chairman and CEO Amit Munshi, an industry veteran with more than 30 years of experience leading biotech companies and most recently the CEO of Arena Pharmaceuticals.

“In order to fulfill our mission to develop RNA medicines with the potential to treat any disease anywhere in the body, we have curated a world-class, multidisciplinary team who have collectively achieved 25 NDAs, including four in RNA medicines, and 200 INDs, and have been pioneers in the field of RNA medicines,” said Amit Munshi, CEO of Renagade. “We are further buoyed by the support of our long-term investors and validated by the progress we have made to date—making us well-positioned to expand the reach of RNA medicine far beyond what was previously thought possible.”

Photo: Amit Munshi, CEO of Renagade Therapeutics